CoChat

Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C

Open access
Ryan, John D., Altamura, Sandro, Devitt, Emma, Mullins, Sarah, Lawless, Matthew W., Muckenthaler, Martina U., Crowe, John · 2012 · Hepatology
Cited by 49

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Pegylated interferon-α (PEG-IFN-α) forms an integral part of the current treatment for hepatitis C virus (HCV) infection. PEG-IFN-α suppresses HCV production by augmenting the innate antiviral immune response. Recent studies have reported the induction of hepcidin, the iron regulatory hormone, by IFN-α in vitro . As hepcidin plays an important role in innate immunity, we hypothesized that this finding may be of clinical relevance to HCV and investigated the changes in iron homeostasis during the first 24 hours of treatment. Blood samples were obtained from HCV patients immediately prior to and 6, 12, and 24 hours following the first dose of PEG-IFN-α/ribavirin (RBV). Samples were analyzed for hepcidin, cytokine, iron levels, and HCV viral load, and hepcidin messenger RNA (mRNA) expression was quantified in peripheral blood mononuclear cells. Hepcidin induction by IFN-α was further analyzed in cell culture. In HCV patients a single dose of PEG-IFN-α/RBV resulted in a significant increase in serum hepcidin, peaking at 12 hours, coinciding with a 50% reduction in serum iron and transferrin saturation over the 24-hour period. Patients with a ≥2 log decline in HCV viral load over the first 24 hours had significantly lower SI and TS levels at 12 and 24 hours. Moreover, 24-hour SI levels were an independent predictor of the immediate HCV viral decline, an indicator of ultimate treatment outcome. In cell culture, a direct induction of hepcidin by IFN-α was seen, controlled by the STAT3 transcription factor. Conclusion : Hepcidin induction occurs following the initiation of PEG-IFN-α treatment for HCV, and is mediated by way of STAT3 signaling. The subsequent hypoferremia was greatest in those with the most significant decline in viral load, identifying systemic iron withdrawal as a marker of immediate interferon-α efficacy in HCV patients. (HEPATOLOGY 2012)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.25666

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 31

  1. Ghany, 2009, Diagnosis, management, and treatment of hepatitis C: an update., HEPATOLOGY, 49, 13351374, 10.1002/hep.22759 · DOI · Paper page
  2. Feld, 2005, Mechanism of action of interferon and ribavirin in treatment of hepatitis C., Nature, 436, 967972, 10.1038/nature04082 · DOI · Paper page
  3. Huang, 2007, Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C., Gastroenterology, 132, 733744, 10.1053/j.gastro.2006.11.045 · DOI
  4. Neumann, 1998, Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferonalpha therapy., Science, 282, 103107, 10.1126/science.282.5386.103 · DOI · Paper page
  5. Devitt, 2010, Early viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24 h., Eur J Gastroenterol Hepatol, 22, 12111220, 10.1097/MEG.0b013e32833caf7b · doi:10.1097/meg.0b013e32833caf7b
  6. DuranteMangoni, 2009, Correlates and prognostic value of the firstphase hepatitis C virus RNA kinetics during treatment., Clin Infect Dis, 49, 498506
  7. Zhang, 2010, Hepcidin expression by human monocytes in response to adhesion and proinflammatory cytokines., Biochim Biophys Acta, 1800, 12621267
  8. Bartolomei, 2011, Modulation of hepatitis C virus replication by iron and hepcidin in Huh7 hepatocytes., J Gen Virol, 92, 20722081, 10.1099/vir.0.032706-0 · DOI
  9. Nemeth, 2004, Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization., Science, 306, 20902093, 10.1126/science.1104742 · DOI · Paper page
  10. Swinkels, 2008, Advances in quantitative hepcidin measurements by timeofflight mass spectrometry., PLoS ONE, 3, e2706, 10.1371/journal.pone.0002706 · DOI · Paper page
  11. van Dijk, 2008, Serum hepcidin levels are innately low in HFErelated haemochromatosis but differ between C282Yhomozygotes with elevated and normal ferritin levels., Br J Haematol, 142, 979985, 10.1111/j.1365-2141.2008.07273.x · DOI · Paper page
  12. Pinto, 2010, Hepcidin messenger RNA expression in human lymphocytes., Immunology, 130, 217230, 10.1111/j.1365-2567.2009.03226.x · DOI · Paper page
  13. Lanford, 2006, Genomic response to interferonalpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics., HEPATOLOGY, 43, 961972, 10.1002/hep.21167 · DOI · Paper page
  14. Ferrara, 2009, Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C., Am J Gastroenterol, 104, 605616
  15. Bonkovsky, 2006, Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C., Gastroenterology, 131, 14401451, 10.1053/j.gastro.2006.08.036 · DOI
  16. Desai, 2008, Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a metaanalysis of six prospective randomized controlled trials., Dig Dis Sci, 53, 815822, 10.1007/s10620-007-9945-7 · DOI
  17. Di Bisceglie, 1992, Measurement of iron status in patients with chronic hepatitis., Gastroenterology, 102, 21082213, 10.1016/0016-5085(92)90339-Z · DOI · Paper page
  18. Bonkovsky, 1997, Iron and chronic viral hepatitis., HEPATOLOGY, 25, 759768, 10.1002/hep.510250345 · DOI · Paper page
  19. Piperno, 1998, Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations., HEPATOLOGY, 28, 11051109, 10.1002/hep.510280427 · DOI · Paper page
  20. Fujita, 2007, Hepatic iron accumulation is associated with disease progression and resistance to interferonribavirin combination therapy in chronic hepatitis C., J Gastroenterol Hepatol, 22, 18861893, 10.1111/j.1440-1746.2006.04759.x · DOI · Paper page
  21. Girelli, 2009, Reduced serum hepcidin levels in patients with chronic hepatitis C., J Hepatol, 51, 845852, 10.1016/j.jhep.2009.06.027 · DOI · Paper page
  22. Kakizaki, 2000, Iron enhances hepatitis C virus replication in cultured human hepatocytes., Liver, 20, 125128, 10.1034/j.1600-0676.2000.020002125.x · DOI · Paper page
  23. Theurl, 2004, Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3., J Infect Dis, 190, 819825, 10.1086/422261 · DOI · Paper page
  24. Fillebeen, 2010, Iron inhibits replication of infectious hepatitis C virus in permissive Huh7.5.1 cells., J Hepatol, 53, 995999, 10.1016/j.jhep.2010.04.044 · DOI
  25. Bonkovsky, 1996, Iron in liver diseases other than hemochromatosis., Semin Liver Dis, 16, 6582, 10.1055/s-2007-1007220 · DOI · Paper page
  26. Kageyama, 2000, Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C., Am J Gastroenterol, 95, 10411050, 10.1111/j.1572-0241.2000.01979.x · DOI · Paper page
  27. Fujita, 2008, Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion., J Hepatol, 49, 702710, 10.1016/j.jhep.2008.05.014 · DOI
  28. Viatte, 2006, Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice., Blood, 107, 29522958, 10.1182/blood-2005-10-4071 · DOI · Paper page
  29. Yang, 1998, STAT3 complements defects in an interferonresistant cell line: evidence for an essential role for STAT3 in interferon signaling and biological activities., Proc Natl Acad Sci U S A, 95, 55685572, 10.1073/pnas.95.10.5568 · DOI · Paper page
  30. Larrea, 2006, Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: in vivo and in vitro studies., Gut, 55, 11881196
  31. Zhang, 1996, STAT3 participates in transcriptional activation of the Creactive protein gene by interleukin6., J Biol Chem, 271, 95039509

Cited by

See all 49

Metadata

Authors
Ryan, J. D., Altamura, S., Devitt, E., Mullins, S., Lawless, M. W., Muckenthaler, M. U., & Crowe, J.
Venue
Hepatology
Published
2012-08
Volume
56
Issue
2
Pages
492-500
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2025954883
Cited by
49
References
18
FWCI
3.91
Type
journal article
Language
en
Open access
bronze
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1126 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.